



Acute exacerbation of idiopathic pulmonary fibrosis after SARS-CoV-2 vaccination

Tomohiro Bando¹, Reoto Takei¹, Yoshikazu Mutoh², Hajime Sasano ¹, Yasuhiko Yamano¹, Toshiki Yokoyama¹, Toshiaki Matsuda¹, Kensuke Kataoka¹, Tomoki Kimura¹ and Yasuhiro Kondoh¹

¹Dept of Respiratory Medicine and Allergy, Tosei General Hospital, Seto, Japan. ²Dept of Infectious Diseases, Tosei General Hospital, Seto, Japan.

Corresponding author: Yasuhiro Kondoh (kondoh@tosei.or.jp)



Shareable abstract (@ERSpublications)

Although the association between acute exacerbation of interstitial lung disease and vaccination is not yet clarified, this is the first case report describing the possibility that SARS-CoV-2 vaccination may trigger acute exacerbation <https://bit.ly/3tpu6Cz>

Cite this article as: Bando T, Takei R, Mutoh Y, *et al.* Acute exacerbation of idiopathic pulmonary fibrosis after SARS-CoV-2 vaccination. *Eur Respir J* 2022; 59: 2102806 [DOI: 10.1183/13993003.02806-2021].

This single-page version can be shared freely online.

Copyright ©The authors 2022.

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org

Received: 27 Oct 2021

Accepted: 23 Dec 2021

To the Editor:

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has spread worldwide and coronavirus disease 2019 remains a major health concern. Several SARS-CoV-2 vaccines have been produced and are playing important roles in the prevention of infection and worsening to a severe state, and in improving mortality [1]. However, some concerns about adverse effects related to SARS-CoV-2 vaccination have been raised. Recently, various adverse effects have been reported, but there is little data on adverse effects on the lungs [2].

